Eli Lilly (LLY) said Friday that data from its VIVID-2 open-label extension study showed bowel disease drug Omvoh, mirikizumab-mrkz, provided long-term clinical remission and endoscopic response to patients with moderately to severely active Crohn's disease as well as for those with prior biologic failure.
Eli Lilly said after two years of treatment, 92.9% of patients in clinical remission at one year remained in remission, while 87.6% maintained endoscopic response with visible healing of the intestinal lining. Of the patients in endoscopic remission at one year of treatment, 78.6% sustained endoscopic remission at two years.
According to the data, 60.8% of patients not in clinical remission at one year achieved remission in the second year. Of those patients not in endoscopic remission at one year, 35.4% gained remission in the second year, the company said.
Eli Lilly said 6.8% of patients with endoscopic response at one year reported a serious adverse event, while 0.8% decided to end the treatment due to an adverse event.
The results will be presented at the Crohn's and Colitis Congress from Feb. 6 to Feb. 8.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.